{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T10:45:54Z","timestamp":1783248354411,"version":"3.54.6"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["2016080"],"award-info":[{"award-number":["2016080"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The infiltration of chronic lymphocytic leukemia (CLL) cells into lymphoid organs correlates with disease severity. CXCL12 is a key chemotactic factor for the trafficking of CLL. Tissue factor pathway inhibitor (TFPI) is a serine protease inhibitor and plays a role in CXCL12-mediated hematopoietic stem cell homing. We aim to explore the role of TFPI in CXCL12-mediated migration of CLL cells. In this study, plasma TFPI concentrations were measured by ELISA. CLL cells were isolated from patients and used for trans-endothelial migration (TEM) assays. Quantitative RT-PCR and Western blotting were used to detect the expression of CXCR7, CXCR4 and \u03b2-catenin. Immunofluorescence and co-immunoprecipitation was used to detect the binding of TFPI and glypican-3 (GPC3).\u00a0We found that plasma TFPI levels in CLL patients were higher than in healthy controls, particularly in the patients with advanced disease. TFPI enhanced CXCL12-mediated TEM of CLL cells by increasing the expression of the CXCL12 receptor CXCR7, but not of the CXCL12 receptor CXCR4. The effect of TFPI on TEM was abolished by the CXCR7 inhibitor, CCX771, while the CXCR4 inhibitor AMD3100 strongly increased TEM. TFPI co-localized with GPC3 on the cell surface. An antibody to GPC3, HS20, decreased CXCR7 expression and abolished the effect of TFPI on TEM. TFPI activated \u03b2-catenin and the Wnt\/\u03b2-catenin inhibitor IWP4 repressed the effect of TFPI on CXCR7 expression and TEM. We conclude that\u00a0TFPI may contribute to organ infiltration in CLL patients.<\/jats:p>","DOI":"10.1038\/s41598-021-84695-8","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T11:03:59Z","timestamp":1614855839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Tissue factor pathway inhibitor upregulates CXCR7 expression and enhances CXCL12-mediated migration in chronic lymphocytic leukemia"],"prefix":"10.1038","volume":"11","author":[{"given":"Xue Yan","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geir Erland","family":"Tj\u00f8nnfjord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip M.","family":"Kanse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Erik Astrup","family":"Dahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane Filion","family":"Myklebust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong Xing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thor","family":"Ueland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Morten","family":"Sandset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"key":"84695_CR1","volume-title":"Chronic Lymphocytic Leukaemia","author":"M Hallek","year":"2018","unstructured":"Hallek, M., Shanafelt, T. D. & Eichhorst, B. Chronic Lymphocytic Leukaemia (Springer, New York, 2018)."},{"key":"84695_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2741\/s251","volume":"4","author":"JF Fecteau","year":"2012","unstructured":"Fecteau, J. F. & Kipps, T. J. Structure and function of the hematopoietic cancer niche: Focus on chronic lymphocytic leukemia. Front. Biosci. 4, 61\u201373 (2012).","journal-title":"Front. Biosci."},{"issue":"1","key":"84695_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1046\/j.1365-2141.1996.00305.x","volume":"92","author":"P Panayiotidis","year":"1996","unstructured":"Panayiotidis, P., Jones, D., Ganeshaguru, K., Foroni, L. & Hoffbrand, A. V. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br. J. Haematol. 92(1), 97\u2013103 (1996).","journal-title":"Br. J. Haematol."},{"issue":"4","key":"84695_CR4","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3109\/10428194.2011.610014","volume":"53","author":"RE Hayden","year":"2012","unstructured":"Hayden, R. E., Pratt, G., Roberts, C., Drayson, M. T. & Bunce, C. M. Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches. Leuk. Lymphoma. 53(4), 537\u2013549 (2012).","journal-title":"Leuk. Lymphoma."},{"key":"84695_CR5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.13055\/ojhmt_3_S1_03.120221","volume":"3","author":"MS Davids","year":"2012","unstructured":"Davids, M. S. & Burger, J. A. Cell trafficking in chronic lymphocytic leukemia. Open J. Hematol. 3, S1 (2012).","journal-title":"Open J. Hematol."},{"issue":"7","key":"84695_CR6","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1182\/blood-2013-03-493924","volume":"123","author":"J Hoellenriegel","year":"2014","unstructured":"Hoellenriegel, J. et al. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood 123(7), 1032\u20131039 (2014).","journal-title":"Blood"},{"issue":"9","key":"84695_CR7","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.leukres.2014.05.017","volume":"38","author":"A Agarwal","year":"2014","unstructured":"Agarwal, A. et al. Genetic and cytokine changes associated with symptomatic stages of CLL. Leuk. Res. 38(9), 1097\u20131101 (2014).","journal-title":"Leuk. Res."},{"issue":"3","key":"84695_CR8","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1084\/jem.184.3.1101","volume":"184","author":"CC Bleul","year":"1996","unstructured":"Bleul, C. C., Fuhlbrigge, R. C., Casasnovas, J. M., Aiuti, A. & Springer, T. A. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J. Exp. Med. 184(3), 1101\u20131109 (1996).","journal-title":"J. Exp. Med."},{"issue":"2","key":"84695_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1182\/blood-2013-05-500496","volume":"123","author":"F Torossian","year":"2014","unstructured":"Torossian, F. et al. CXCR7 participates in CXCL12-induced CD34+ cell cycling through beta-arrestin-dependent Akt activation. Blood 123(2), 191\u2013202 (2014).","journal-title":"Blood"},{"issue":"9","key":"84695_CR10","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1084\/jem.20052144","volume":"203","author":"JM Burns","year":"2006","unstructured":"Burns, J. M. et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med. 203(9), 2201\u20132213 (2006).","journal-title":"J Exp Med."},{"issue":"8","key":"84695_CR11","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1158\/0008-5472.CAN-09-3642","volume":"70","author":"K Hattermann","year":"2010","unstructured":"Hattermann, K. et al. The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res. 70(8), 3299\u20133308 (2010).","journal-title":"Cancer Res."},{"issue":"4","key":"84695_CR12","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.4049\/jimmunol.176.4.2197","volume":"176","author":"S Infantino","year":"2006","unstructured":"Infantino, S., Moepps, B. & Thelen, M. Expression and regulation of the orphan receptor RDC1 and its putative ligand in human dendritic and B cells. J. Immunol. 176(4), 2197\u20132207 (2006).","journal-title":"J. Immunol."},{"key":"84695_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1476-4598-10-73","volume":"10","author":"BA Zabel","year":"2011","unstructured":"Zabel, B. A., Lewen, S., Berahovich, R. D., Jaen, J. C. & Schall, T. J. The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells. Mol. Cancer. 10, 73 (2011).","journal-title":"Mol. Cancer."},{"issue":"23","key":"84695_CR14","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1182\/blood-2014-04-565358","volume":"123","author":"TN Hartmann","year":"2014","unstructured":"Hartmann, T. N. CLL cells under flow. Blood 123(23), 3533\u20133534 (2014).","journal-title":"Blood"},{"issue":"19","key":"84695_CR15","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1182\/blood-2013-11-512764","volume":"123","author":"JP Wood","year":"2014","unstructured":"Wood, J. P., Ellery, P. E., Maroney, S. A. & Mast, A. E. Biology of tissue factor pathway inhibitor. Blood 123(19), 2934\u20132943 (2014).","journal-title":"Blood"},{"issue":"9","key":"84695_CR16","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1172\/JCI7750","volume":"104","author":"EG Fischer","year":"1999","unstructured":"Fischer, E. G. et al. Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor. J. Clin. Invest. 104(9), 1213\u20131221 (1999).","journal-title":"J. Clin. Invest."},{"issue":"9","key":"84695_CR17","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1182\/blood-2003-07-2234","volume":"103","author":"TA Hembrough","year":"2004","unstructured":"Hembrough, T. A. et al. Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity. Blood 103(9), 3374\u20133380 (2004).","journal-title":"Blood"},{"key":"84695_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/1471-2407-11-357","volume":"11","author":"B Stavik","year":"2011","unstructured":"Stavik, B. et al. Downregulation of TFPI in breast cancer cells induces tyrosine phosphorylation signaling and increases metastatic growth by stimulating cell motility. BMC Cancer. 11, 357 (2011).","journal-title":"BMC Cancer."},{"issue":"3","key":"84695_CR19","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/cas.13485","volume":"109","author":"Y Shimizu","year":"2018","unstructured":"Shimizu, Y. et al. Cancer immunotherapy-targeted glypican-3 or neoantigens. Cancer Sci. 109(3), 531\u2013541 (2018).","journal-title":"Cancer Sci."},{"issue":"14","key":"84695_CR20","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1182\/blood-2012-09-456715","volume":"121","author":"S Khurana","year":"2013","unstructured":"Khurana, S. et al. Glypican-3-mediated inhibition of CD26 by TFPI: A novel mechanism in hematopoietic stem cell homing and maintenance. Blood 121(14), 2587\u20132595 (2013).","journal-title":"Blood"},{"issue":"Pt 7","key":"84695_CR21","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1242\/jcs.140871","volume":"127","author":"M Capurro","year":"2014","unstructured":"Capurro, M., Martin, T., Shi, W. & Filmus, J. Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling. J. Cell Sci. 127(Pt 7), 1565\u20131575 (2014).","journal-title":"J. Cell Sci."},{"key":"84695_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ctrv.2017.11.002","volume":"62","author":"N Krishnamurthy","year":"2018","unstructured":"Krishnamurthy, N. & Kurzrock, R. Targeting the Wnt\/beta-catenin pathway in cancer: Update on effectors and inhibitors. Cancer Treat. Rev. 62, 50\u201360 (2018).","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"84695_CR23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s12015-014-9515-2","volume":"10","author":"A Ring","year":"2014","unstructured":"Ring, A., Kim, Y. M. & Kahn, M. Wnt\/catenin signaling in adult stem cell physiology and disease. Stem Cell Rev. 10(4), 512\u2013525 (2014).","journal-title":"Stem Cell Rev."},{"issue":"12","key":"84695_CR24","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek, M. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12), 5446\u20135456 (2008).","journal-title":"Blood"},{"issue":"2","key":"84695_CR25","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/hep.26996","volume":"60","author":"W Gao","year":"2014","unstructured":"Gao, W. et al. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy. Hepatology 60(2), 576\u2013587 (2014).","journal-title":"Hepatology"},{"issue":"2","key":"84695_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","volume":"46","author":"KR Rai","year":"1975","unstructured":"Rai, K. R. et al. Clinical staging of chronic lymphocytic leukemia. Blood 46(2), 219\u2013234 (1975).","journal-title":"Blood"},{"issue":"1","key":"84695_CR27","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","volume":"48","author":"JL Binet","year":"1981","unstructured":"Binet, J. L. et al. A new prognostic classification of chronic lymphocytic-leukemia derived from a multivariate survival analysis. Cancer 48(1), 198\u2013206 (1981).","journal-title":"Cancer"},{"issue":"11","key":"84695_CR28","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.1182\/blood-2002-10-3188","volume":"101","author":"A Dahm","year":"2003","unstructured":"Dahm, A. et al. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 101(11), 4387\u20134392 (2003).","journal-title":"Blood"},{"issue":"3","key":"84695_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.bcmd.2013.05.003","volume":"51","author":"XY Cui","year":"2013","unstructured":"Cui, X. Y. et al. Hypoxia influences stem cell-like properties in multidrug resistant K562 leukemic cells. Blood Cells Mol. Dis. 51(3), 177\u2013184 (2013).","journal-title":"Blood Cells Mol. Dis."},{"issue":"2","key":"84695_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/jth.13206","volume":"14","author":"XY Cui","year":"2016","unstructured":"Cui, X. Y. et al. Effect of hypoxia on tissue factor pathway inhibitor expression in breast cancer. J. Thromb. Haemost. 14(2), 387\u2013396 (2016).","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"84695_CR31","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.4049\/jimmunol.0900269","volume":"183","author":"BA Zabel","year":"2009","unstructured":"Zabel, B. A. et al. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J. Immunol. 183(5), 3204\u20133211 (2009).","journal-title":"J. Immunol."},{"issue":"4","key":"84695_CR32","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3324\/haematol.2011.052779","volume":"97","author":"B Stamatopoulos","year":"2012","unstructured":"Stamatopoulos, B. et al. AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: Pre-clinical evidence for its association with chronic lymphocytic leukemia treatments. Haematologica 97(4), 608\u2013615 (2012).","journal-title":"Haematologica"},{"issue":"Pt 2","key":"84695_CR33","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1042\/bj3270577","volume":"327","author":"AE Mast","year":"1997","unstructured":"Mast, A. E. et al. Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor. Biochem J. 327(Pt 2), 577\u2013583 (1997).","journal-title":"Biochem J."},{"issue":"3","key":"84695_CR34","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1074\/jbc.M410090200","volume":"280","author":"HH Song","year":"2005","unstructured":"Song, H. H., Shi, W., Xiang, Y. Y. & Filmus, J. The loss of glypican-3 induces alterations in Wnt signaling. J. Biol. Chem. 280(3), 2116\u20132125 (2005).","journal-title":"J. Biol. Chem."},{"issue":"12","key":"84695_CR35","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/sj.leu.2401602","volume":"13","author":"R Mohle","year":"1999","unstructured":"Mohle, R., Failenschmid, C., Bautz, F. & Kanz, L. Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1). Leukemia 13(12), 1954\u20131959 (1999).","journal-title":"Leukemia"},{"issue":"1","key":"84695_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13287-017-0765-1","volume":"9","author":"RCC Melo","year":"2018","unstructured":"Melo, R. C. C., Ferro, K. P. V., Duarte, A. & Olalla Saad, S. T. CXCR7 participates in CXCL12-mediated migration and homing of leukemic and normal hematopoietic cells. Stem Cell Res. Ther. 9(1), 34 (2018).","journal-title":"Stem Cell Res. Ther."},{"issue":"1\u20132","key":"84695_CR37","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3109\/10428190109097671","volume":"42","author":"B Gu","year":"2001","unstructured":"Gu, B., Dao, L. P. & Wiley, J. Impaired transendothelial migration of B-CLL lymphocytes: A defect linked to low L-selectin expression. Leuk. Lymphoma. 42(1\u20132), 5\u201312 (2001).","journal-title":"Leuk. Lymphoma."},{"issue":"24","key":"84695_CR38","doi-asserted-by":"publisher","first-page":"5081","DOI":"10.1182\/blood-2009-03-210617","volume":"114","author":"EM Trinidad","year":"2009","unstructured":"Trinidad, E. M., Ballesteros, M., Zuloaga, J., Zapata, A. & Alonso-Colmenar, L. M. An impaired transendothelial migration potential of chronic lymphocytic leukemia (CLL) cells can be linked to ephrin-A4 expression. Blood 114(24), 5081\u20135090 (2009).","journal-title":"Blood"},{"issue":"7","key":"84695_CR39","doi-asserted-by":"publisher","first-page":"e11716","DOI":"10.1371\/journal.pone.0011716","volume":"5","author":"M O'Hayre","year":"2010","unstructured":"O\u2019Hayre, M. et al. Elucidating the CXCL12\/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis. PLoS ONE 5(7), e11716 (2010).","journal-title":"PLoS ONE"},{"issue":"24","key":"84695_CR40","doi-asserted-by":"publisher","first-page":"6085","DOI":"10.1182\/blood-2008-12-196618","volume":"113","author":"A Levoye","year":"2009","unstructured":"Levoye, A., Balabanian, K., Baleux, F., Bachelerie, F. & Lagane, B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 113(24), 6085\u20136093 (2009).","journal-title":"Blood"},{"issue":"1","key":"84695_CR41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.neuron.2010.12.005","volume":"69","author":"Y Wang","year":"2011","unstructured":"Wang, Y. et al. CXCR4 and CXCR7 have distinct functions in regulating interneuron migration. Neuron 69(1), 61\u201376 (2011).","journal-title":"Neuron"},{"issue":"8","key":"84695_CR42","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1002\/stem.2022","volume":"33","author":"Q Chen","year":"2015","unstructured":"Chen, Q. et al. CXCR7 mediates neural progenitor cells migration to CXCL12 independent of CXCR4. Stem Cells. 33(8), 2574\u20132585 (2015).","journal-title":"Stem Cells."},{"issue":"5","key":"84695_CR43","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1124\/mol.108.053389","volume":"75","author":"I Kalatskaya","year":"2009","unstructured":"Kalatskaya, I. et al. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol. Pharmacol. 75(5), 1240\u20131247 (2009).","journal-title":"Mol. Pharmacol."},{"issue":"6","key":"84695_CR44","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1182\/blood-2004-09-3422","volume":"105","author":"J Ahamed","year":"2005","unstructured":"Ahamed, J., Belting, M. & Ruf, W. Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor 1. Blood 105(6), 2384\u20132391 (2005).","journal-title":"Blood"},{"key":"84695_CR45","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.matbio.2013.12.007","volume":"35","author":"J Filmus","year":"2014","unstructured":"Filmus, J. & Capurro, M. The role of glypicans in Hedgehog signaling. Matrix Biol. 35, 248\u2013252 (2014).","journal-title":"Matrix Biol."},{"issue":"12","key":"84695_CR46","doi-asserted-by":"publisher","first-page":"7576","DOI":"10.1074\/jbc.M114.612705","volume":"290","author":"M Capurro","year":"2015","unstructured":"Capurro, M., Shi, W., Izumikawa, T., Kitagawa, H. & Filmus, J. Processing by convertases is required for glypican-3-induced inhibition of Hedgehog signaling. J. Biol. Chem. 290(12), 7576\u20137585 (2015).","journal-title":"J. Biol. Chem."},{"key":"84695_CR47","doi-asserted-by":"publisher","first-page":"26245","DOI":"10.1038\/srep26245","volume":"6","author":"W Gao","year":"2016","unstructured":"Gao, W., Xu, Y., Liu, J. & Ho, M. Epitope mapping by a Wnt-blocking antibody: evidence of the Wnt binding domain in heparan sulfate. Sci. Rep. 6, 26245 (2016).","journal-title":"Sci. Rep."},{"issue":"2","key":"84695_CR48","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/labinvest.2015.144","volume":"96","author":"K Yang","year":"2016","unstructured":"Yang, K. et al. The evolving roles of canonical WNT signaling in stem cells and tumorigenesis: Implications in targeted cancer therapies. Lab. Invest. 96(2), 116\u2013136 (2016).","journal-title":"Lab. Invest."},{"issue":"9","key":"84695_CR49","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1073\/pnas.0308648100","volume":"101","author":"D Lu","year":"2004","unstructured":"Lu, D. et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA. 101(9), 3118\u20133123 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"issue":"7","key":"84695_CR50","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1182\/blood-2014-01-552067","volume":"124","author":"L Wang","year":"2014","unstructured":"Wang, L. et al. Somatic mutation as a mechanism of Wnt\/beta-catenin pathway activation in CLL. Blood 124(7), 1089\u20131098 (2014).","journal-title":"Blood"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84695-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84695-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84695-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T04:43:14Z","timestamp":1670042594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84695-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["84695"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-84695-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,4]]},"assertion":[{"value":"1 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5127"}}